Neupogen (Filgrastim)

Filgrastim binds to the G‑CSF receptor on bone‑marrow progenitor cells, triggering intracellular pathways that stimulate the proliferation, differentiation, and activation of neutrophil precursors, thereby increasing the number of functional neutrophils in the bloodstream.

The dose of Neupogen is individualized by the prescribing clinician based on the patient’s condition, weight, and treatment protocol. Healthcare providers determine the exact amount, frequency, and route of administration for each case.

Neupogen is classified as Pregnancy Category C, indicating that risk cannot be ruled out. It should only be used if the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should consult their physician, as filgrastim may be present in breast milk.

To order Neupogen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and necessary import documentation.

The primary alternative to Neupogen is pegfilgrastim (e.g., Neulasta), a long‑acting pegylated form of filgrastim that requires only a single injection per chemotherapy cycle. Neupogen, being non‑pegylated, often requires daily dosing but offers flexibility in timing and dose adjustments.

Neupogen must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. Once reconstituted, use the solution immediately or store according to the manufacturer’s instructions, typically for a limited period at controlled temperature.

Neupogen is supplied as a lyophilized powder that is reconstituted with sterile water for injection. The resulting solution can be given intravenously or subcutaneously, as directed by the prescriber, using aseptic technique and appropriate injection equipment.

Serious adverse events include splenic rupture, anaphylactic reactions, and capillary leak syndrome. Patients should be instructed to seek immediate medical attention if they experience sudden abdominal pain, signs of severe allergic reaction, or unexplained rapid swelling and low blood pressure.

Neupogen is contraindicated in individuals with known hypersensitivity to filgrastim or any of its excipients. Caution is advised for patients with sickle cell disease, severe renal impairment, or those who have experienced splenic rupture previously.